Answers are grounded in this paper and cite their sources.
Background: Magnesium (Mg) deficiency contributes to the pathophysiology of numerous diseases, and the therapeutic use of Mg has steadily increased by consumers over time. The increased in-hospital use of intravenous (IV) magnesium sulfate (MgSO4) warrants more extensive study regarding the safety of the therapy. The aim of this study was to determine the safety of IV MgSO4 infusion on cardiovascular, liver, kidney, and metabolic markers in adults.Methods: Twelve volunteers were randomized to one of two conditions: (a) IV infusion of MgSO4 in 5% dextrose followed by IV infusion of 5% dextrose 1 week later or (b) IV infusion of 5% dextrose followed by IV infusion of MgSO4 in 5% dextrose 1 week later. An electrocardiogram was monitored continuously throughout the course of the infusions. Blood was drawn pre- and post-infusions for complete blood count/chemistry, high-density lipoprotein and low-density lipoprotein cholesterol, and triglycerides.Results: Serum Mg increased from pre- to post-infusion in the MgSO4 + 5% dextrose group (p<0.0001). The QRS interval length increased from pre- to post-infusion in the MgSO4 + 5% dextrose group (p<0.04). Additionally, serum glucose concentration increased in the MgSO4 + 5% dextrose group (p = 0.04). These significant findings were modeled with gender and age as covariates. No other significant differences were found.Conclusions: The administration of IV infusion of MgSO4 (4 g/100 mL) in 5% dextrose over a 4-hour treatment period poses no significant deleterious effects on cardiovascular, liver, kidney, or metabolic function.Relevance for patients: IV infusion of MgSO4 may be used for proper treatment indications without significant concern for adverse effects on cardiovascular, liver, kidney, or metabolic function.
No takes yet. Share an insight, caveat, or question.
John E. Lewis (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: